

## EXN169

**Name:** EXN 169

**Synonyms:** Serine/threonine-protein kinase 1 (SRPK1)-mediated VEGF splicing ; SPHINXes; SRPK1 inhibitors

**Indication:** wet Age-Related Macular Degeneration

**Company:** Exonate

Exonate have developed small molecules that inhibit production of pro-angiogenic VEGF through selective inhibition of serine/threonine-protein kinase 1 (SRPK1)-mediated VEGF splicing. These inhibitors have already demonstrated superior efficacy as topical agents in preclinical models of wet AMD.

Targeting diseases through regulation of VEGF isoforms/variants that are both protective and disease promoting. Exonate's lead program is focused on wet Age-Related Macular Degeneration, (wet AMD), which is the leading cause of vision loss in people aged 60 and older. The Company is founded on scientific excellence with strong links to Prof. David Bates and his lab at Nottingham University specialising in the biology and biochemical pathways of VEGF splice variants. In addition Exonate has formed academic collaborations with the university of New South Wales (Australia) and Professor Jonathan Morris.

Exonate is developing eye drops to revolutionise the current standard-of-care in the treatment of eye diseases. Exonate, an early stage biotechnology company, today announces the launch of its newly developed website. The website has been created by the team at Onespacemedia, an award winning digital agency based in the heart of Cambridge.

Onespacemedia were commissioned by Exonate to develop a strong, contemporary and sector appropriate web presence and to elevate the Company's profile using leading design techniques. Exonate wanted to enhance visibility of its science, demonstrate momentum and increase business development and partnership enquiries online. The new website portrays the need for and Exonate's commitment to developing a revolutionary, game changing eye drop for the treatment of retinal vascular diseases, including wet Age-related Macular degeneration (wAMD) and Diabetic Macular Oedema (DME), by using mRNA targeted therapies.